QualityStocks Stock Newsletters Archives - Page 685 of 1818

MondaySep 21, 2009 8:22 pm

Arrayit Corp. (ARYC.OB) Wins Equipment Contract from Sandia National Laboratories

Arrayit Corp., a developer and manufacturer of proprietary life science technologies and consumables for disease prevention, treatment and cure, recently announced that the company delivered its proprietary nanotechnology platform to Sandia National Laboratories in Albuquerque, New Mexico on September 11, 2009. Arrayit Corporation offers over 650 products to a customer base of more than 2,500 laboratories worldwide. Managed by the Lockheed Martin Corporation, Sandia Labs collaborates with the Transportation Security Administration (TSA) and the Department of Homeland Security to enhance national security. These highly sensitive detection devices deliver system deposits nanoliter quantities of analytical reagents onto proprietary substrates to create…

MondaySep 21, 2009 8:21 pm

Nutra Pharma (NPHC.OB) Announces Pertinent Product Information

Nutra Pharma has announced their intention to begin the registration for their over-the-counter pain reliever in both Canada and Europe. Currently, the company is marketing a similar product, Cobroxin, within the United States. Cobroxin is used for the treatment of moderate to severe (Stage 2) chronic pain. According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reports that chronic pain effects one in five adults across Europe. Dr. Paul Redi, CEO…

MondaySep 21, 2009 2:00 pm

Manhattan Scientifics Inc. (MHTX.OB) Inks Licensing Agreement with Carpenter Technology

Manhattan Scientifics Inc. capitalizes on inventions and technology by earning profits through licensing. It identifies, develops, patents, supports and markets these innovations to bring them into the marketplace. The company today announced an agreement with Carpenter Technology Corp. (NYSE: CRS) in which Carpenter will develop, manufacture and market a new class of high-strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. “Carpenter continues to forge ahead as the leading developer of stainless steels and specialty alloys,” Anne L. Stevens, Carpenter’s chairman and CEO stated in the press release. “Our relationship with Manhattan Scientifics will…

MondaySep 21, 2009 1:57 pm

Axial Vector Energy Corp. (AXVC.PK) Describes Dual Technologies of Petrosonics

Axial Vector Energy Corp., developer of advanced, high-efficiency energy engines, has access to two important fuel purification technologies associated with Petrosonics LLC, the privately held development stage oil refining technology company that is part of the PETROAVEC joint venture between Axial Vector and Petrosonics. The first technology uses ultrasound at moderate temperature and atmospheric pressure to reduce sulfur and nitrogen in processed diesel. This is important because there is worldwide legislation aimed at decreasing sulfur emissions to zero, including emissions from off-road use such as marine and locomotive. There is also a shift in demand from gasoline to diesel. Hydrotreatment,…

MondaySep 21, 2009 1:51 pm

Neuralstem, Inc. (CUR) Receives FDA Approval to Begin First ALS Stem Cell Trial

Neuralstem Inc. has patented technology which enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities. The company's technology also has the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous systems diseases such as Amyotrophic Lateral Sclerosis (ALS), better known as Lou Gehrig's disease. The company announced today that the US Food & Drug Administration (FDA) has approved its investigational new drug application to commence a Phase 1 trial to treat ALS or…

MondaySep 21, 2009 10:05 am

DOR BioPharma Inc. (DORB.OB) Earns $9.4 Million NIH Grant

DOR BioPharma Inc. is a late-stage biotechnology company that has been gaining national attention for its state-of-the-art technology. DOR reached a major milestone in the advancement of its company with the announcement that it has been awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases, which is a division of the National Institute of Health (NIH). This grant will assist the company’s future over the next five years with the development of formulation and manufacturing processes for vaccines, including RiVax(TM), that are stable at elevated temperatures. The grant will also fund the development of improved…

MondaySep 21, 2009 9:59 am

GlaxoSmithKline (GSK) and XenoPort, Inc. (XNPT) Report Positive Results from Clinical Trial

Friday, GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (NASDAQ:XNPT) announced top-line results from a Phase II-b clinical trial. The study evaluates the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain, associated with post-herpetic neuralgia (PHN) in adults. The company reported that subjects were randomized to receive placebo, 1200, 2400 or 3600 mg/day of GSK1838262 dosed twice a day; all patients treated with GSK1838262 demonstrated statistically significant improvements over the control group. The primary endpoint was the change from baseline to the end of maintenance treatment in the 24-hour average pain intensity score. The 14-week, double-blind study enrolled 376 subjects with…

MondaySep 21, 2009 9:57 am

Speedus Corp. (SPDE) Subsidiary Receives Clearance to Market Signal X6 Device

Siemens Corporate Research spin-off and Speedus Corp. subsidiary, Zargis Medical Corp., announced Friday that it has received U.S. Food and Drug Administration clearance to market the new Signal X6(TM) device. The company also announced that seven Signal X6 devices have been delivered to the U.S. Army for deployment in six Department of Defense medical facilities. Signal X6 technology records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, when a cardiac specialist is not immediately available, transmitted through the Internet for remote evaluation. This feature makes the noninvasive technology easy to use. The configuration…

FridaySep 18, 2009 2:49 pm

FieldPoint Petroleum Corp.’s (FPP) $4.4M Acquisition Could be its “Most Important Acquisition”

FieldPoint Petroleum Corp. is an oil and gas exploration, production and acquisition company primarily focused on Louisiana, New Mexico, Oklahoma, Texas and Wyoming. The company today announced the $4.4 million acquisition of a working interest in Texas. Per the agreement, effective September 1, 2009, FieldPoint will acquire a 74 percent to 100 percent working interest in the Block Field in Andrews County, Texas, as well as net revenue interests between 59 percent and 87.5 percent in leasehold and equipment. The field is expected to generate roughly 204,000 barrel of oil equivalent (BOE) in proved developed producing reserves based on a…

FridaySep 18, 2009 11:51 am

Keryx Biopharmaceuticals, Inc. (KERX.OB) Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma

Keryx Biopharmaceuticals, Inc., a developer of medically important pharmaceutical products for the treatment of life-threatening diseases, recently announced that the company has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for KRX-0401 (perifosine) for the treatment of multiple myeloma. Multiple myeloma is a cancer of the plasma cells. Although incurable, this disease, which represents 1 percent of all cancer diagnoses and 2 percent of all cancer deaths, is treatable. According to the American Cancer Society, there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United…

Site Search

Company Search

Category: QualityStocks Stock Newsletters